Study on the correlation between serum CTHRC1 and CX3CL1 levels and prognosis in patients with oral implant restorations

doi:10.11958/20240714

Abstract

Abstract:

Objective To investigate seserum levels of collagen triple helix repeat containing protein-1 (CTHRC1) and C-X3-C motif chemokine ligand 1 (CX3CL1) and their correlation with prognosis in patients undergoing oral implant restorations. Methods A total of 247 patients underwent oral implant restorations were selected as the implant restoration group, and 247 healthy subjects who underwent medical checkups during the same period were selected as the control group. Serum CTHRC1 and CX3CL1 levels were detected by enzyme-linked immunosorbent assay (ELISA) at 1 week preoperatively, 1 week postoperatively and 1 month postoperatively in the 2 groups. According to the X-ray examination results of the patients at 6 month after surgery, patients were separated into the poor prognosis group (28 cases) and the good prognosis group (219 cases). C-reactive protein (CRP), interleukin 6 (IL-6), CTHRC1 and CX3CL1 levels were compared in patients at 1 month postoperatively. Multifactor COX regression was applied to analyze factors influencing poor prognosis of implants. Results Compared with the control group, there were no significant changes in serum CTHRC1 and CX3CL1 levels in the implant restoration group at 1 week preoperatively (P>0.05), and serum CTHRC1 and CX3CL1 levels were elevated at 1 week postoperatively and at 1 month postoperatively (P<0.05). The serum levels of CTHRC1 and CX3CL1 showed a trend of first increasing and then decreasing one week before surgery, one week after surgery and one month after surgery in the implant repair group. One week after surgery reached the highest (426.85±73.52) μg/L and (142.41±15.26 ) ng/L, respectively. There was a positive correlation between CTHRC1 and CX3CL1 in patients with oral implant restoration (r=0.436, P<0.001). The inflammatory factors CRP, IL-6, CTHRC1 and CX3CL1 were obviously higher in the poor prognosis group than those in the good prognosis group (P<0.05). Multifactor COX regression analysis showed that both CTHRC1 and CX3CL1 were independent influencing factors for poor implant prognosis in patients underwent oral implant restorations (P<0.05). Conclusion Serum CTHRC1 and CX3CL1 levels are upregulated in patients with poor prognosis for oral implant restorations, and both are independent influencing factors on patient prognosis.

Key words: prognosis, oral implant repair surgery, collagen triple helix repeat containing protein-1, C-X3-C motif chemokine ligand 1

CLC Number:

R783

Figures/Tables 4

References 23

[1]	杨丽媛, 刘冠邑, 赵凌, 等. 3种方法确定水平颌位关系的全口义齿准确性比较[J]. 华西口腔医学杂志, 2020, 38(4):404-409.
	YANG L Y, LIU G Y, ZHAO L, et al. Comparison of the aceuracy of three methods for determining maxillomandibular horizontal relationship of the completedenture[J]. West China Journal of Stomatology, 2020, 38(4):404-409. doi:10.7518/hxkg.2020.04.009.
[2]	曹雪, 朱桃燕, 孙应明, 等. 口腔种植修复对牙列缺损患者功能改善情况的观察[J]. 河北医药, 2020, 42(7):1032-1035.
	CAO X, ZHU T Y, SUN Y M, et al. The improvement status in patients with dentition defect after dental implant prosthesis[J]. Hebei Medical, 2020, 42(7):1032-1035. doi:10.3969/i.issn.1002-7386.2020.07.016.
[3]	李昊, 叶枝茂, 罗诒财, 等. 增强miR-185-5p表达可减轻小鼠实验性牙周炎的炎症反应[J]. 中国组织工程研究, 2023, 27(35):5676-5680.
	LI H, YE Z M, LUO Y C, et al. Enhanced miR-185-5p expression attenuates inflammatory responses in a mouse model of experimental periodontitis[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(35):5676-5680. doi:10.12307/2023.892.
[4]	PANDEY C, ROKAYA D, BHATTARAI B P. Contemporary concepts in osseointegration of dental implants:a review[J]. Biomed Res Int, 2022, 13(1):617-626. doi:10.1155/2022/6170452.
[5]	GARCIA R, DOPICO J, KALEMAJ Z, et al. Comparison of clinical outcomes of immediate versus delayed placement of dental implants:A systematic review and meta-analysis[J]. Clin Oral Implants Res, 2022, 33(3):231-277. doi:10.1111/clr.13892.
[6]	GUO Y, JIANG C, YAO S, et al. CTHRC1 knockdown promotes inflammatory responses partially by p38 MAPK activation in human periodontal ligament cells[J]. Inflammation, 2021, 44(5):1831-1842. doi:10.1007/s10753-021-01461-8.
[7]	SHEN R, CAI X, SHEN D, et al. Long noncoding RNA LINC00518 contributes to proliferation and metastasis in lung adenocarcinoma via the miR-335-3p/CTHRC1 axis[J]. Cell Death Discovery, 2022, 8(1):98-107. doi:10.1038/s41420-022-00905-w.
[8]	梁月明, 张培芳, 魏晓群, 等. 慢性阻塞性肺疾病患者血清S100A8/A9、CX3CL1联合检测的临床价值[J]. 国际检验医学杂志, 2021, 42(22):2740-2744.
	LIANG Y M, ZHANG P F, WEI X Q, et al. Clinical value of combined detection of serum S100A8/A9 and CX3CLl in patientswith chronic obstructive pulmonary disease[J]. Int J Lab Med, 2021, 42(22):2740-2744. doi:10.3969/j.issn.1673-4130.2021.22.011.
[9]	HAO W, LI M, ZHANG C, et al. Increased levels of inflammatory biomarker CX3CL1 in patients with chronic obstructive pulmonary disease[J]. Cytokine, 2020, 126(1):154-163. doi:10.1016/j.cyto.2019.154881.
[10]	范清林, 范圣杰. 口腔种植修复与常规修复治疗牙列缺损患者及预后影响分析[J]. 全科口腔医学电子杂志, 2020, 7(5):45-46.
	FAN Q L, FAN S J. Analysis of patients and prognostic impact of oral implant restorations versus conventional restorations for the treatment of edentulous teeth and prognosis[J]. Electronic Journal of General Stomatology, 2020, 7(5):45-46.
[11]	常忠福, 姜丹丹, 张志荣, 等. 口腔种植修复术在牙列缺损患者中的应用效果及对龈沟液中TNF-α、IL-6水平的影响[J]. 上海口腔医学, 2020, 29(2):217-220.
	CHANG Z F, JIANG D D, ZHANG Z R, et al. Effect of oral implant restoration on dentition defeet patients and its impact on TNF-α and IL-6 levels ingingival crevicular fuid[J]. Shanghai Joumal of Stomatology, 2020, 29(2):217-220. doi:10.19439/j.sjos.2020.02.020.
[12]	赵国强, 丁锋, 刘益, 等. T2DM患者即刻种植预后及影响因素的回顾性研究[J]. 实用口腔医学杂志, 2022, 38(1):74-79.
	ZHAO G Q, DING F, LIU Y, et al. Prognosis and influencing factors of immediate implantation in T2DM patients:A retrospective study[J]. J Pract Stomatol, 2022, 38(1):74-79. doi:10.3969/i.issn.1001-3733.2022.01.015.
[13]	高星, 叶甲舟, 朴雪岷, 等. 轴突导向因子G1在肝细胞癌患者血清和组织中的表达及其临床意义[J]. 中国癌症防治杂志, 2021, 13(6):634-640.
	GAO X, YE J Z, PIAO X M, et al. Expression of netrin-G1 in serum and tissues of patients with hepatocellular carcinoma andits clinical significance[J]. Chin J Oncol Prev Treat, 2021, 13(6):634-640. doi:10.3969/i.issn.1674-5671.2021.06.11.
[14]	周辉芳, 隗和儒, 马士朝, 等. 胶原三股螺旋重复蛋白1基因真核表达载体的构建及其与microRNA-30b关系初探[J]. 临床肝胆病杂志, 2020, 36(2):377-380.
	ZHOU H F, WEI H R, MA S Z, et al. Construction of the eukaryotie expression vector of collagen triple helix repeat containing 1 gene and its associationwith microRNA -30b[J]. Journal of Clinical Hepatobiliary Disease, 2020, 36(2):377-380. doi:10.3969/j.issn.1001-5256.2020.02.029.
[15]	MEI D, ZHU Y, ZHANG L, et al. The role of CTHRC1 in regulation of multiple signaling and tumor progression and metastasis[J]. Mediators Inflamm, 2020, 12(1):957-966. doi:10.1155/2020/9578701.
[16]	MYNGBAY A, MANARBEK L, LUDBROOK S, et al. The role of collagen triple helix repeat-containing 1 protein (CTHRC1) in rheumatoid arthritis[J]. Int J Mol Sci, 2021, 22(5):2426-2435. doi:10.3390/ijms22052426.
[17]	DUAN X, YUAN X, YAO B, et al. The role of CTHRC1 in promotion of cutaneous wound healing[J]. Signal Transduct Target Ther, 2022, 7(1):183-147. doi:10.1038/s41392-022-01008-9.
[18]	杨茜茜, 崔吉正, 赵志斌, 等. 趋化因子CX3CL1和受体CX3CR1在中枢神经系统疾病中的进展[J]. 医学研究生学报, 2020, 33(4):416-421.
	YANG Q Q, CUI J Z, ZHAO Z B, et al. Progress of CX3CL1 and its receptor CX3CRl in regulating central neryous system disease[J]. J Med Poslgra, 2020, 33(4):416-421. doi:10.16571/i.cnki.1008-8199.2020.04.015.
[19]	王学方, 归荣, 陈功义, 等. 连花柴芩可溶性粉对鸡风热犯肺证的临床试验研究[J]. 中国畜牧兽医, 2022, 49(9):3610-3621.
	WANG X F, GUI R, CHEN G Y, et al. Clinical study of lianhuachaigin soluble powder on chickensyndrome of wind-heat invading lung[J]. China Animal Husbandry and Veterinary Medicine, 2022, 49(9):3610-3621. doi:10.16431/i.cnki.1671-7236.2022.09.035.
[20]	LU Z, ZHANG A, DAI Y. CX3CL1 deficiency ameliorates inflammation,apoptosis and accelerates osteogenic differentiation,mineralization in LPS-treated MC3T3-E1 cells via its receptor CX3CR1[J]. Ann Anat, 2023, 246(1):152-161. doi:10.1016/j.aanat.2022.152036.
[21]	MIKOLAJCZYK T P, SZCZEPANIAK P, VIDLER F, et al. Role of inflammatory chemokines in hypertension[J]. Pharmacol Ther, 2021, 223(1):107-116. doi:10.1016/j.pharmthera.2020.107799.
[22]	MERINO J J, CABAÑA-MUÑOZ M E, TOLEDANO GASCA A, et al. Elevated systemic L-kynurenine/L-tryptophan ratio and increased IL-1 beta and chemokine (CX3CL1,MCP-1) proinflammatory mediators in patients with long-term titanium dental implants[J]. J Clin Med, 2019, 8(9):1368-1382. doi:10.3390/jcm8091368.
[23]	李碧榕, 孟维艳. NLRP3炎症小体在种植体周围炎中的研究进展[J]. 口腔医学研究, 2022, 38(12):1119-1123.
	LI B R, MENG W Y. Research progres of NLRP3 inflammasome in peri-implantitis[J]. Journal of Oral Science Research, 2022, 38(12):1119-1123. doi:10.13701/j.cnki.kqyxyj.2022.12.004.

组别	n	时间点	CTHRC1/（μg/L）	CX3CL1/（ng/L）
对照组	247		137.26±21.15	106.68±11.75
种植修复组	247	术前1周	137.18±23.24	107.47±11.58
		术后1周	426.85±73.52^a	142.41±15.26^a
		术后1个月	232.39±31.65^ab	124.16±13.47^ab
t₁			0.029	0.948
t₂			105.855^＊	42.865^＊
t₃			34.773^＊	20.971^＊
F			2 490.827^＊	409.615^＊

组别	n	时间点	CTHRC1/（μg/L）	CX3CL1/（ng/L）
对照组	247		137.26±21.15	106.68±11.75
种植修复组	247	术前1周	137.18±23.24	107.47±11.58
		术后1周	426.85±73.52^a	142.41±15.26^a
		术后1个月	232.39±31.65^ab	124.16±13.47^ab
t₁			0.029	0.948
t₂			105.855^＊	42.865^＊
t₃			34.773^＊	20.971^＊
F			2 490.827^＊	409.615^＊

组别	n		年龄/ 岁		性别（男/女）	抗生素服用（是/否）		BMI/ （kg/m²）		TC/ （mmol/L）
预后良好组	219		38.84±7.15		107/112	196/23		24.17±2.93		3.62±0.88
预后不良组	28		39.68±9.76		16/12	24/4		24.82±3.58		3.73±0.95
t或χ²			0.437		0.682	0.365		0.937		0.674
组别		TG/ （mmol/L）		HDL-C/ （mmol/L）			LDL-C/ （mmol/L）		CRP/ （mg/L）		IL-6/ （μg/L）
预后良好组		1.56±0.17		1.14±0.17			2.72±0.31		1.96±0.21		0.14±0.02
预后不良组		1.62±0.18		1.08±0.14			2.84±0.36		3.05±0.52		0.27±0.04
t或χ²		1.670		1.967			1.870		11.150^＊		15.210^＊

组别	n		年龄/ 岁		性别（男/女）	抗生素服用（是/否）		BMI/ （kg/m²）		TC/ （mmol/L）
预后良好组	219		38.84±7.15		107/112	196/23		24.17±2.93		3.62±0.88
预后不良组	28		39.68±9.76		16/12	24/4		24.82±3.58		3.73±0.95
t或χ²			0.437		0.682	0.365		0.937		0.674
组别		TG/ （mmol/L）		HDL-C/ （mmol/L）			LDL-C/ （mmol/L）		CRP/ （mg/L）		IL-6/ （μg/L）
预后良好组		1.56±0.17		1.14±0.17			2.72±0.31		1.96±0.21		0.14±0.02
预后不良组		1.62±0.18		1.08±0.14			2.84±0.36		3.05±0.52		0.27±0.04
t或χ²		1.670		1.967			1.870		11.150^＊		15.210^＊

组别	n	CTHRC1/（μg/L）	CX3CL1/（ng/L）
预后良好组	219	215.63±62.65	122.25±26.49
预后不良组	28	363.48±82.18	139.15±20.68
t		9.185^＊	3.252^＊